



Universiteit  
Leiden  
The Netherlands

## **Antithrombin, protein C, and protein S: genome and transcriptome-wide association studies identify 7 novel loci regulating plasma levels**

Ji, Y.K.; Temprano-Sagrera, G.; Holle, L.A.; Bebo, A.; Brody, J.A.; , N.Q. le; ... ; INVENT Consortium

### **Citation**

Ji, Y. K., Temprano-Sagrera, G., Holle, L. A., Bebo, A., Brody, J. A., Kangro, K., ... Sabater-Lleal, M. (2023). Antithrombin, protein C, and protein S: genome and transcriptome-wide association studies identify 7 novel loci regulating plasma levels. *Arteriosclerosis, Thrombosis, And Vascular Biology*, 43(7), E254-E269. doi:10.1161/ATVBAHA.122.318213

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3722085>

**Note:** To cite this publication please use the final published version (if applicable).

## CLINICAL AND POPULATION STUDIES



# Antithrombin, Protein C, and Protein S: Genome and Transcriptome-Wide Association Studies Identify 7 Novel Loci Regulating Plasma Levels

Yuekai Ji,\* Gerard Temprano-Sagrera<sup>1</sup>,\* Lori A. Holle<sup>2</sup>, Allison Bebo, Jennifer A. Brody<sup>3</sup>, Ngoc-Quynh Le, Kadri Kangro<sup>4</sup>, Michael R. Brown<sup>5</sup>, Angel Martinez-Perez<sup>6</sup>, Colleen M. Sitlani<sup>7</sup>, Pierre Suchon, Marcus E. Kleber, David B. Emmert, Ayse Bilge Ozel, Dre'Von A. Dobson<sup>8</sup>, Weihong Tang<sup>9</sup>, Dolores Llobet, Russell P. Tracy<sup>10</sup>, Jean-François Deleuze, Graciela E. Delgado, Martin Gögele<sup>11</sup>, Kerri L. Wiggins<sup>12</sup>, Juan Carlos Souto<sup>13</sup>, James S. Pankow<sup>14</sup>, Kent D. Taylor<sup>15</sup>, David-Alexandre Trégouët<sup>16</sup>, Angela P. Moissl<sup>17</sup>, Christian Fuchsberger, Frits R. Rosendaal<sup>18</sup>, Alanna C. Morrison<sup>19</sup>, Jose Manuel Soria<sup>20</sup>, Mary Cushman<sup>21</sup>, Pierre-Emmanuel Morange, Winfried März, Andrew A. Hicks<sup>22</sup>, Karl C. Desch, Andrew D. Johnson<sup>23</sup>, Paul S. de Vries<sup>24</sup>, CHARGE Consortium Hemostasis Working Group, INVENT Consortium, Alisa S. Wolberg<sup>25</sup>, Nicholas L. Smith<sup>26</sup>,† Maria Sabater-Lleal<sup>27</sup>†

**BACKGROUND:** Antithrombin, PC (protein C), and PS (protein S) are circulating natural anticoagulant proteins that regulate hemostasis and of which partial deficiencies are causes of venous thromboembolism. Previous genetic association studies involving antithrombin, PC, and PS were limited by modest sample sizes or by being restricted to candidate genes. In the setting of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, we meta-analyzed across ancestries the results from 10 genome-wide association studies of plasma levels of antithrombin, PC, PS free, and PS total.

**METHODS:** Study participants were of European and African ancestries, and genotype data were imputed to TOPMed, a dense multiancestry reference panel. Each of the 10 studies conducted a genome-wide association studies for each phenotype and summary results were meta-analyzed, stratified by ancestry. Analysis of antithrombin included 25 243 European ancestry and 2688 African ancestry participants, PC analysis included 16 597 European ancestry and 2688 African ancestry participants, PSF and PST analysis included 4 113 and 6 409 European ancestry participants. We also conducted transcriptome-wide association analyses and multiphenotype analysis to discover additional associations. Novel genome-wide association studies and transcriptome-wide association analyses findings were validated by in vitro functional experiments. Mendelian randomization was performed to assess the causal relationship between these proteins and cardiovascular outcomes.

**RESULTS:** Genome-wide association studies meta-analyses identified 4 newly associated loci: 3 with antithrombin levels (*GCKR*, *BAZ1B*, and *HP-TXNL4B*) and 1 with PS levels (*ORM1-ORM2*). transcriptome-wide association analyses identified 3 newly associated genes: 1 with antithrombin level (*FCGRT*), 1 with PC (*GOLM2*), and 1 with PS (*MYL7*). In addition, we replicated 7 independent loci reported in previous studies. Functional experiments provided evidence for the involvement of *GCKR*, *SNX17*, and *HP* genes in antithrombin regulation.

**CONCLUSIONS:** The use of larger sample sizes, diverse populations, and a denser imputation reference panel allowed the detection of 7 novel genomic loci associated with plasma antithrombin, PC, and PS levels.

**GRAPHIC ABSTRACT:** A graphic abstract is available for this article.

**Key Words:** anticoagulant ■ antithrombin ■ genome-wide association study ■ genotype ■ hemostasis ■ protein C ■ protein S

Correspondence to: Maria Sabater-Lleal, PhD, Genomics of Complex Disease Unit, Sant Pau Biomedical Research Institute (IIB Sant Pau), St Quintí 77-79, 08041, Barcelona, Spain, Email msabater@santpau.cat; or Nicholas L. Smith, PhD, Cardiovascular Health Research Unit, University of Washington, 1730 Minor Ave, Ste 1360, Seattle, WA 98101, Email nlsmith@u.washington.edu

\*Y.J. and G.T.-S. contributed equally as first authors.

†N.L.S. and M.S.-L. contributed equally as last authors.

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/ATVBAHA.122.318213>.

For Sources of Funding and Disclosures, see page e266.

© 2023 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at [www.ahajournals.org/journal/atvb](http://www.ahajournals.org/journal/atvb)

## Nonstandard Abbreviations and Acronyms

|             |   |
|-------------|---|
| <b>AA</b>   | African ancestry                        |
| <b>AGP</b>  | $\alpha$ 1-acid-glycoprotein            |
| <b>CAD</b>  | coronary artery disease                 |
| <b>CRP</b>  | C-reactive protein                      |
| <b>EA</b>   | European ancestry                       |
| <b>EAF</b>  | effect allele frequency                 |
| <b>eQTL</b> | expression quantitative trait locus     |
| <b>GWAS</b> | genome-wide association study           |
| <b>LDL</b>  | low-density lipoprotein                 |
| <b>PC</b>   | protein C                               |
| <b>PS</b>   | protein S                               |
| <b>TWAS</b> | transcriptome-wide association analyses |
| <b>VTE</b>  | venous thromboembolism                  |

See accompanying editorial on page 1322

Antithrombin, PC (protein C), and PS (protein S) are circulating anticoagulant proteins, and low levels or low activity of these proteins are associated with the risk of venous thromboembolism (VTE).<sup>1–4</sup> Genetic variants in the protein-coding genes for antithrombin, PC, and PS (*SERPINC1*, *PROC*, and *PROS1*, respectively)<sup>5–7</sup> have been studied for decades, and rare mutations have been associated both with low protein levels and with risk of VTE.<sup>5,8–11</sup> There have been at least 6 agnostic genome-wide association studies (GWAS) for antithrombin, PC, and PS, with sample sizes ranging from 351 (antithrombin) to 13968 (PC). For antithrombin, no additional genome-wide significant loci beyond *SERPINC1* were identified.<sup>12,13</sup> For PC, significant loci at the *GCKR* and *BAZ1B* genes had been identified in European ancestry (EA) populations,<sup>14,15</sup> and the *CELSR2-PSRC1-SORT1*, *PROC*, and *PROCR* loci were identified in both EA and African ancestry (AA) populations.<sup>13,15–17</sup> For PS, no genome-wide significant associations have been found. In this report, using larger sample sizes, diverse populations, and a denser imputation reference panel, we sought to identify novel genomic loci associated with plasma antithrombin, PC, and PS levels.

## METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request. GWAS summary statistics are accessible through dbGAPs.

## Overview

We used densely imputed genotypes to perform cross-ancestry (antithrombin and PC) and EA-only (PS) GWAS meta-analyses and attempted replication of the lead variants using available summary data from a proteomics-based study.<sup>18</sup> This was

## Highlights

- Using cross-ancestry genome-wide association study and transcriptome-wide association analyses methods, we report 4 novel loci regulating antithrombin plasma levels, 2 novel loci regulating PS (protein S) plasma levels, and 1 novel locus regulating PC (protein C) plasma levels.
- Post-genome-wide association study analyses and functional work suggest both *SNX17* and *GCKR* are regulators of antithrombin on the chromosome 2 locus and validate an AA-specific *HP* gene locus.
- MR analyses provide evidence implicating low antithrombin levels in venous thromboembolism risk and low PC levels in venous thromboembolism and coronary artery disease risk.

followed by a multiphenotype analysis and transcriptome-wide association analyses (TWAS) in EA individuals. For characterization and prioritization of genes, we used colocalization and fine-mapping analyses, and novel GWAS findings were functionally interrogated. Last, we conducted Mendelian randomization (MR) analyses to assess causal relationships with cardiovascular clinical events. Figure 1 is a schematic summarizing our approach.


## Study Design and Participating Studies

The setting for the meta-analysis was the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium Hemostasis Working Group.<sup>19</sup> We included data from 10 studies from the US and Europe that measured 1 or more of the 3 natural anticoagulants in plasma, by antigen or activity methods. Study details including genotype and phenotype measurement, study design, population, and baseline time are found in [Tables S1 and S2](#), and [Supplemental Material](#).<sup>13,15,20–32</sup> In total, 27 606 EA and 2688 AA participants were included: 25 243 EA and 2688 AA participants for antithrombin; 16 597 EA and 2688 AA participants for PC; and 4113 and 6409 EA participants for PS. There were no AA participants with PS measures and too few non-EA/non-AA individuals with other measurements to perform meaningful association analyses. All studies were approved by appropriate research ethics committees and all participants provided informed consent.

## Discovery Analysis

### Study-Specific Genome-Wide Association Analyses

Each study imputed measured genotypes to the transomic for precision medicine) reference panel before association analyses.<sup>33</sup> Study-specific quality control was implemented before the analysis. Details about genotyping platforms and specific quality control parameters can be found in [Table S2](#). Each study followed a common analysis plan that required performing linear regression within each ancestry group, adjusting for sex, age, principal components, and study-specific variables, which included a kinship matrix when necessary to account for family structure. Details of the measures of the 3 natural anticoagulants and on regression methods can be found in [Table S2](#) and [Supplemental Methods](#).



**Figure 1.** Schematic view of the analysis's workflow.

### Population-Specific and Cross-Ancestry Meta-Analysis

Quality control across studies was conducted using EasyQC.<sup>34</sup> Details of meta-analysis quality control can be found in [Supplemental Material](#). We meta-analyzed study-level summary results using METAL software, first by phenotype measure (antigen or activity), then by ancestry. Only variants appearing in at least 2 studies were retained in the final meta-analyses. Cross-ancestry meta-analyses were conducted on those phenotypes that included EA and AA participants (antithrombin and PC). No other ancestries groups were available. Meta-analyses were performed by 2 analysts in parallel and compared for consistency.

The significance threshold<sup>35</sup> was set at  $5 \times 10^{-9}$ . A locus was defined as 1 Mb upstream and downstream of the variant with the lowest *P* value. Genome-wide significant variants with MAF < 1%, present in 2 studies or fewer, or with inconsistent beta directions between studies were not considered.

### Conditional Analysis

We performed approximate conditional and joint analyses for all variants with MAF > 1% using summary statistics from ancestry-specific meta-analyses (see [Supplemental Methods](#)).

### Replication

We sought for replication of associations for the identified lead variants in an external dataset, using available summary data from DeCODE Genetics (see [Supplemental Methods](#)).

### Transcriptome-Wide Association Analyses

We used GWAS results and S-PrediXcan and S-MultiXcan<sup>36,37</sup> to perform transcriptome-wide analyses for each phenotype within the EA populations to infer significant associations between the *cis* component of gene expression and the phenotypes. See detailed methods in [Supplemental Methods](#).

### Multiphenotype Meta-Analysis

We jointly analyzed the 4 meta-analyses results (cross-ancestry meta-analyses for antithrombin and PC, and the 2 EA PS meta-analyses) using a multiphenotype method implemented in the metaUSAT R package 1.17.<sup>38</sup> Significant multiphenotype associations were defined as any genome-wide significant lead variants in the multivariate analysis (*P* values<sub>multivariate</sub> for the lead variant  $< 5 \times 10^{-9}$ ), which were also nominally significant in a least 2 of the phenotypes individually (*P* value<sub>univariate</sub> < 0.005).<sup>39</sup> Additionally, we considered novel variants to be those that were not genome-wide significant for any of the 4 phenotypes individually, or that had not been associated with antithrombin, PC, PS free or total in a previous GWAS for antithrombin, PC, PS free, or total. Lead variants for each phenotype found in the discovery (Table 1) were queried using the HaploR R package v4.0.6 to extract functional annotations and biological information (Table S4). Further details are reported in [Supplemental Methods](#).

**Table 1. GWAS and Post-GWAS Evidence of Candidate Genes**

| GWAS evidence   |             |           |                  |          |  |   | Status   | Post-GWAS evidence   |              |   |                             |
|-----------------|-------------|-----------|------------------|----------|--|---|--|--|--------------|---|-----------------------------|
| Chr:Pos:A1:A2   | rsID        | EA        | Beta (SE)        | N        | P value  | Consequence                               |  | TWAS   | Fine mapping | Colocalization                              | Functional work             |
| Antithrombin    |             |           |                  |          |  |   |  |  |              |   |                             |
| 1:173914872:A:T | rs2227624   | 0.994     | 8.13 (0.2)       |          | 5.31×10 <sup>-19</sup>                           | MV to <i>SERPINC1</i>                     | Known association  | <i>SERPINC1</i><br><i>ZBTB3</i><br><i>DARS2</i><br><i>RABGAP1L</i><br><i>TNN</i>                   | ...          | <i>SERPINC1</i><br><i>TNN</i>               | <i>SERPINC1</i>             |
|                 |             | 0.994 EA  | 8.19 (0.91) EA   | 24414 EA | 3.33×10 <sup>-19</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.999 AA  | -5.93 (13.36) AA | 2688 AA  | 0.6572 AA  |   |  |  |              |   |                             |
| 2:27375230:T:C  | rs4665972   | 0.443     | 0.98 (0.1)       |          | 6.74×10 <sup>-16</sup>                           | IV to <i>SNX17</i>                        | Novel GWAS Association with replication (3.16×10 <sup>-6</sup> )   | <i>GCKR</i>  | <i>NRBP1</i> | <i>GTF3C2-AS2</i>                           | <i>SNX17</i><br><i>GCKR</i> |
|                 |             | 0.447 EA  | 0.99 (0.12) EA   | 25242 EA | 7.87×10 <sup>-16</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.086 AA  | 0.71 (1.19) AA   | 2688 AA  | 0.5485 AA  |   |  |  |              |   |                             |
| 7:73497513:T:C  | rs13244268  | 0.891     | 1.14 (0.2)       |          | 3.91×10 <sup>-9</sup>                            | IV to <i>BAZ1B</i>                        | Novel GWAS Association with replication (0.0017)                   | <i>MLXIPL</i><br><i>BCL7B</i>  | ...          | ...   | ...                         |
|                 |             | 0.890 EA  | 1.13 (0.2) EA    | 25095 EA | 5.88×10 <sup>-9</sup> EA                         |   |  |  |              |   |                             |
|                 |             | 0.957 AA  | 1.44 (1.59) AA   | 2688 AA  | 0.3644 AA  |   |  |  |              |   |                             |
| 16:72054562:A:C | rs5471      | 0.874     | 9.82 (0.92)      |          | 1.72×10 <sup>-26</sup>                           | IV to <i>HP</i> , 5' UTR to <i>TXNL4B</i> | Novel GWAS association   | ...  | ...          | <i>HP</i>                                   | <i>HP</i>                   |
|                 |             | 0.993 EA  | 10.56 (3.57) EA  | 12774 EA | 0.0031 EA  |   |  |  |              |   |                             |
|                 |             | 0.866 AA  | 9.77 (0.95) AA   | 2688 AA  | 1.37×10 <sup>-24</sup> AA                        |   |  |  |              |   |                             |
| 19:49513222:T:G | rs111981233 | 0.917     | -1.12 (0.22)     |          | 3.23×10 <sup>-7</sup>                            | IV to <i>FCGRT</i>                        | Novel TWAS association   | <i>FCGRT</i>   | ...          | <i>FCGRT</i><br><i>RCN3</i><br><i>RPS11</i> | -                           |
|                 |             | 0.916 EA  | -1.13 (0.22) EA  | 25095 EA | 3.28×10 <sup>-7</sup> EA                         |   |  |  |              |   |                             |
|                 |             | 0.961 AA  | -0.6 (1.69) AA   | 2688 AA  | 0.7230 AA  |   |  |  |              |   |                             |
| Protein C       |             |           |                  |          |  |   |  |  |              |   |                             |
| 1:109274968:T:G | rs12740374  | 0.226     | -0.09 (0.01)     |          | 1.52×10 <sup>-13</sup>                           | 3' UTR to <i>CELSR2</i>                   | Known association  | <i>PSRC1</i><br><i>PSMA5</i>   | <i>PSRC1</i> | ...   | ...                         |
|                 |             | 0.220 EA  | -0.086 (0.01) EA | 15556 EA | 1.09×10 <sup>-10</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.258 AA  | -0.12 (0.03) AA  | 2688 AA  | 2.07×10 <sup>-4</sup> AA                         |   |  |  |              |   |                             |
| 2:127418299:A:G | rs1799809   | 0.540     | 0.20 (0.01)      |          | 1.71×10 <sup>-90</sup>                           | 0.1 KB 5' to <i>PROC</i>                  | Known association  | <i>PROC</i>  | <i>PROC</i>  | ...   | ...                         |
|                 |             | 0.569 EA  | 0.21 (0.01) EA   | 16597 EA | 5.10×10 <sup>-83</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.392 AA  | 0.17 (0.03) AA   | 2688 AA  | 1.11×10 <sup>-8</sup> AA                         |   |  |  |              |   |                             |
| 2:27375230:T:C  | rs4665972   | 0.405     | 0.11 (0.01)      |          | 7.10×10 <sup>-24</sup>                           | IV to <i>SNX17</i>                        | Known association  | <i>GCKR</i><br><i>PPM1G</i><br><i>NRBP1</i><br><i>KRTCAP3</i><br><i>SLC4A1AP</i><br><i>C2orf16</i> | <i>NRBP1</i> | ...   | ...                         |
|                 |             | 0.420 EA  | 0.11 (0.01) EA   | 16597 EA | 1.78×10 <sup>-23</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.086 AA  | 0.08 (0.05) AA   | 2688 AA  | 0.1361 AA  |   |  |  |              |   |                             |
| 7:73625076:C:G  | rs35493868  | 0.810     | 0.08 (0.01)      |          | 5.87×10 <sup>-10</sup>                           | 2KB 5' to <i>MLXIPL</i>                   | Known association  | <i>MLXIPL</i><br><i>TBL2</i>   | ...          | ...   | ...                         |
|                 |             | 0.805 EA  | 0.08 (0.01) EA   | 16597 EA | 8.64×10 <sup>-10</sup> EA                        |   |  |  |              |   |                             |
|                 |             | 0.855 AA  | 0.05 (0.04) AA   | 2688 AA  | 0.2170 AA  |   |  |  |              |   |                             |
| 15:42980693:T:C | rs529330569 | 0.006     | 0.46 (0.08)      |          | 1.2×10 <sup>-8</sup><br>5.31×10 <sup>-9</sup> EA | IV to <i>UBR1</i>                         | Novel TWAS association   | <i>GOLM2</i><br><i>LCMT2</i><br><i>CATSPER2</i>  | <i>LCMT2</i> | ...   | ...                         |
|                 |             | 0.006 EA  | 0.47 (0.08) EA   | 15341 EA | 0.4336 AA  |   |  |  |              |   |                             |
|                 |             | 0.0004 AA | -0.54 (0.69) AA  | 2688 AA  |  |   |  |  |              |   |                             |
| 20:35179967:T:C | rs11907011  | 0.091     | 0.74 (0.02)      |          | 4.72×10 <sup>-395</sup>                          | IV to <i>PROCR</i>                        | Known association  | <i>PROCR</i>   | <i>PROCR</i> | ...   | ...                         |
|                 |             | 0.094 EA  | 0.75 (0.02) EA   | 16597 EA | 6.99×10 <sup>-362</sup> EA                       |   |  |  |              |   |                             |
|                 |             | 0.063 AA  | 0.68 (0.06) AA   | 2688 AA  | 1.23×10 <sup>-33</sup> AA                        |   |  |  |              |   |                             |
| Protein S       |             |           |                  |          |  |   |  |  |              |   |                             |
| 3:93868695:T:C  | rs528128538 | 0.011     | -27.92 (3.4)     | 4006     | 2.04×10 <sup>-16</sup>                           | 1KB 5' to <i>PROS1</i>                    | Known association  | <i>PROS1</i>   | ...          | ...   | No Model                    |
| 7:444568571:T:C | rs141292869 | 0.003     | 22.13 (5.26)     | 3718     | 2.54×10 <sup>-5</sup>                            | IV to <i>DDX56</i>                        | Novel TWAS association   | <i>MYL7</i>  | ...          | ...   | No Model                    |
| 9:114321523:A:C | rs150611042 | 0.088 PSF | -8.12 (0.89) PSF | 4006 PSF | 9.24×10 <sup>-20</sup> PSF                       | 2KB 5' to <i>ORM1</i>                     | Novel GWAS association with replication (7.53×10 <sup>-102</sup> ) | <i>ORM2</i>  | ...          | ...   | No Model                    |
|                 |             | 0.081 PST | -6.14 (0.76) PST | 6257 PST | 7.65×10 <sup>-16</sup> PST                       |   |  |  |              |   |                             |

(Continued)

**Table 1. Continued**

| GWAS evidence   |            |           |               |          |                        |                  | Status                             | Post-GWAS evidence |              |                |                 |
|-----------------|------------|-----------|---------------|----------|------------------------|------------------|------------------------------------|--------------------|--------------|----------------|-----------------|
| Chr:Pos:A1:A2   | rsID       | EA        | Beta (SE)     | N        | P value                | Consequence      |                                    | TWAS               | Fine mapping | Colocalization | Functional work |
| 7:45231101:A:T  | rs59569024 | 0.001     | -57.92 (13.4) | 1975     | 1.54×10 <sup>-5</sup>  | 380KB 5' to MYL7 | Novel TWAS association             | ...                | ...          | ...            | No Model        |
| Multiphenotype  |            |           |               |          |                        |                  |                                    |                    |              |                |                 |
| 15:43528519:T:C | rs55707100 | 0.034     | ...           | 51955 EA | 1.64×10 <sup>-13</sup> | MV to MAP1A      | Novel multiphenotype association.* | -                  | -            | -              | -               |
|                 |            | 0.034 EA  |               | 5376 AA  |                        |                  |                                    |                    |              |                |                 |
|                 |            | 0.0034 AA |               |          |                        |                  |                                    |                    |              |                |                 |

3'UTR indicates 3 prime untranslated region; 5'UTR, 5 prime untranslated region; A1, effect allele; A2, other allele; AA, African ancestry; EA, European ancestry; IV, intronic variant; MV, missense variant; PSF, protein S free; and PST, protein S total.

\*Overlapping with novel TWAS association for PC.

## Characterization and Prioritization of Candidate Loci

### Fine-Mapping and Colocalization

In all GWAS associated loci, we performed fine-mapping using FOCUS, and colocalization using COLOC and HyPrColoc. Detailed methods for fine-mapping and colocalization can be found in the [Supplemental Methods](#).

### Gene Prioritization

For all genes within 1 Mb of the lead variant from novel GWAS associated loci, we selected the closest gene to the lead variant, genes that had a TWAS significant *P* value on the prioritized tissues, genes that had fine-mapping posterior inclusion probability equal or higher than 0.95, genes that had a conditional probability of colocalization equal to or higher than 0.8, and genes with relevant functional annotations in HaploR, for example. Additionally, we selected all TWAS significant genes in the 5 prioritized tissues. Finally, to qualify for in vitro functional validation, prioritized genes were additionally required to be expressed in liver (>10 transcripts per million in GTex) and in HepG2 cells (>10 nTPM, Human Protein Atlas). Figure 2 shows gene prioritization steps, and [Table S5](#) shows the specific genes selected for each phenotype.

### In Vitro Functional Validation

Functional validation of prioritized candidates was performed by in vitro silencing of candidate genes in a liver-derived hepatoblastoma (HepG2) cell expression system. Briefly, HepG2 cells were reverse-transfected with small-interfering RNA (siRNA) against candidate genes. Cells were counted, and target proteins and genes were characterized by immunoblot of cell supernatants and RT-qPCR, respectively. Details on cell culture, transfection, RNA extraction, RT-qPCR, and immunoblotting methods can be found in [Supplemental Methods](#).

### Mendelian Randomization

Two-sample summary statistics-based MR was used to assess the association of genetically determined levels of antithrombin and PC with the risk of venous thromboembolism (VTE), VTE (42078 cases and 424073 controls),<sup>40,41</sup> peripheral artery disease (31307 cases and 211753 controls),<sup>42</sup> coronary artery disease (CAD; 60801 cases and 123504 controls),<sup>43</sup> and ischemic stroke (60341 cases and 454450 controls).<sup>44</sup> We used instrumental variants from our GWAS results as main analyses.

Additional details on methods are reported on [Supplemental Methods](#). Given the small proportion of variance explained by the identified PS variants we did not investigate PS ( $PS_{free}$  and  $PS_{total}$ ) in MR analyses because of insufficient number of genetic instruments. We then additionally validated our analyses using weights derived from deCODE genetics data.<sup>18</sup>

## RESULTS


Antithrombin activity (% or IU/mL×100, n=26999) or antigen (IU/mL×100; n=932) was measured in 9 studies, PC activity (% or IU/mL×100; n=6734) or antigen (µg/mL; n=12551) was measured in 8 studies, PS Total ( $PS_{total}$ ) activity (% or IU/mL×100 or IU/mL; n=5045) or antigen (IU/mL or µg/dL; n=1363) was measured in 7 studies, and PS Free ( $PS_{free}$ ) activity (µg/dL or %; n=1998) or antigen (IU/mL×100; n=2115) was measured in 6 studies. See [Table S6](#).

### Antithrombin

#### Genome-Wide Association Studies

The antithrombin meta-analysis include 25243 EA and 2688 AA participants. After quality control and filtering, 80168840 variants remained in the meta-analysis. All  $\lambda_{GC}$  for individual GWAS were 1.04 or below for all chromosomes. Additional details about quality control are provided in [Table S7](#) and [Supplemental Material](#). Manhattan plots for the overall cross-ancestry meta-analyses are shown in Figure 3. A quantile-to-quantile plot (QQ plot) of *P* values for these variants is presented in [Figure S1](#) and Manhattan plots for the EA and AA population-specific analyses are available at [Figure S2](#).

In total, variants in 4 loci exceeded the established genome-wide significance level in the cross-ancestry analysis, 2 loci in the EA-specific analysis and 1 locus in the AA-specific analysis. Forest plots for significant variants can be found in [Figure S3](#). Loci at *SNX17-GCKR-NRBP1* (2p23.3), *MLXIPL-BAZ1B-BCL7B* (7q11.23), and *HP-TXNL4B* (16q22.2) were new associations. The association at *HP-TXNL4B* (16q22.2) was only found in the AA population. Lead variants in the cross-ancestry



**Figure 2. Prioritization steps of functional analysis.**

CPC indicates conditional probability of colocalization; GWAS, genome-wide association study; PIP, posterior inclusion probability; TPM, transcripts per million; and TWAS, transcriptome-wide association study.

meta-analysis in each region are listed in Table 1 along with the meta-analysis *P* value, ancestry-specific *P* value, effect allele frequency (EAF), beta estimates, and closest gene.

No significant heterogeneity was found in the direction or magnitude of beta coefficients for any of the lead variants associated with antithrombin, within or between ancestries. Conditional analyses using the population-specific meta-analyses (Table S8) identified no additional independent variants on *SNX17-GCKR-NRBP1* and *HP-TXNL4B* surrounding regions. On chromosome 1 locus (*SERPINC1*), we found 1 variant (rs182221508, MAF=0.0017) intronic to *RABGAP1L* gene (600 kb

upstream the lead variant), which was independent from the lead missense variant rs2227624 on *SERPINC1* gene.

Table S9 shows the lead variants with the strongest associations in the EA and AA meta-analyses. There was 1 significant locus in the AA population-specific analysis at chromosomal position 16q22.2 (*HP-TXNL4B*), which also appeared in cross-ancestry analysis. In the EA-specific population analysis, the results reflected cross-ancestry findings at 1q25.1 (*SERPINC1*) and 2p23.3 (*SNX17-GCKR-NRBP1*), with a different lead variant on chromosome 2: rs4665972, located in an intronic region of *SNX17*, was the lead variant in the cross-ancestry analysis, while rs11127048, 150 kb upstream rs4665972 and located in an intergenic region between *SNX17* and *GCKR* genes was the lead variant in the EA-specific analysis. We did not find significant signals at 7q11.23 in the EA-specific analysis. The proportion of variance explained by the independent lead variants was 1.4% in EA and 4.3% in AA, of the total antithrombin variance.

All lead variants from GWAS were replicated in the deCODE summary results derived from SOMAScan measures of these anticoagulants (all  $P < 0.05/11 = 4.5 \times 10^{-3}$ ), except for the lead variant of the chromosome 16 locus, which was specific for the AA population and was not present in the DeCODE data (Table 1; Table S10).

**Transcriptome-Wide Association Analyses**

TWAS analyses identified associated genes in 4 different loci (Figure 3A). Associations on chromosomes 1 (*SERPINC1*), 2 (*GKCR*), and 7 (*MLXIPL*), identified by the strongest associated gene in the TWAS, matched associated loci found in the GWAS. Additionally, the *FCGRT* gene represented a new association on chromosome 19. The smallest GWAS *P* value for this region approached significance and was for a rare intronic variant (rs111981233) in *FCGRT* gene (Figure 3; Table S11) that was replicated in the DeCODE study (Table 1; Table S10).


**Fine Mapping**

EA-specific fine-mapping results prioritized the *SERPINC1* gene on chromosome 1 and the *NRBP1* gene on chromosome 2. Given that FOCUS only prioritizes GWAS hits at TWAS risk loci, loci on chromosomes 16 (only GWAS) or 19 (only TWAS) could not be further explored for gene prioritization. In addition, after correcting for LD and pleiotropic effects, none of genes in chromosome 7 locus was included in the credible set, suggesting a regulation mechanism that does not involve gene expression (Table S12).

**Colocalization**

We obtained 2 significant colocalizations in lead variants located in the new antithrombin loci (conditional probability of colocalization >0.8) and gene expression of nearby genes. On chromosome 2, *GTF3C2-AS2* (at

Downloaded from http://ahajournals.org by on March 11, 2024



**Figure 3. Manhattan plots for discovery meta-analyses of genome-wide association study (GWAS; up) and transcriptome-wide association study (TWAS; down) results.**

**A**, Antithrombin **(B)** protein C **(C)** protein S free **(D)** protein S total. Dots represent all allelic variants (GWAS) or genes (TWAS) sorted by chromosome and position throughout the x axis. y axis report inverse log transformed  $P$  value for the associations.

*SNX17-GCKR-NRBP1* locus) gene expression in artery tibial tissue colocalized with antithrombin plasma levels and on chromosome 16 locus, *HP* gene expression in liver and whole blood also colocalized with antithrombin plasma regulation (Table S13).

### Functional Validation

We selected 1 to 3 genes per locus for functional analysis (4 genes total) based on the gene prioritization criteria described above (Figure 2; Table S5): *SNX17*, *GCKR*, *NRBP1* (Chr 2), and *HP* (Chr 16). Genes in the newly associated locus on chromosome 7, and the gene associated in TWAS on chromosome 19 were not included because no expression was detected in HepG2 cells for of the selected genes (*BAZ1B*, *BCL7B*, *FCGRT*) or for biological implausibility (*MLXIPL*). We transfected HepG2 cells with siRNA against each candidate gene and confirmed that target gene expression was significantly reduced ( $P < 0.005$ ). We then characterized effects of the gene knockdowns on cell count; *NRBP1* silencing significantly reduced the cell count and was removed from the screen (Figure S4). Finally, we quantified antithrombin expression by immunoblot of cell supernatants and *SERPINC1* expression by RT-qPCR. As expected, control experiments showed that treatment of HepG2 cells with lipofectamine (alone) or siRNA against *PROC* did not significantly alter antithrombin (protein) or *SERPINC1* (gene) expression, whereas silencing *SERPINC1* significantly suppressed antithrombin and *SERPINC1* expression (Figure 4A and 4B). Quantification of immunoblots revealed that silencing *GCKR* enhanced, whereas silencing *SNX17* and *HP* suppressed, antithrombin protein production (Figure 4A). The *GCKR*-dependent increase in antithrombin was associated with a significant increase in *SERPINC1* expression, suggesting *GCKR* negatively regulates antithrombin gene expression (Figure 4B). The *SNX17*-dependent loss of antithrombin was associated with a trend toward decreased *SERPINC1* expression

( $P < 0.09$ ), suggesting *SNX17* positively regulates antithrombin gene expression (Figure 4B). Interestingly, *HP*-dependent loss of antithrombin was not accompanied by a significant decrease in *SERPINC1* expression (Figure 4B) suggesting effects of *HP* on antithrombin production are manifested via a post-transcriptional mechanism.

### MR Analysis

For the main analyses, we used 4 genetic instruments derived from our GWAS data (Table S14) to investigate the association between antithrombin levels and VTE and peripheral artery disease, and 3 to investigate its association with CAD and ischemic stroke. We detected a significant deleterious effect of genetically determined low antithrombin levels and risk of VTE (IVW OR, 0.84 [0.72–0.97];  $P$  value: 0.015; Figure 5A). Sensitivity analyses showed consistent effect in size and direction with MR Egger, MR weighted median, and MR weighted mode (Table S15; Figure S5). Leave-one-out sensitivity analyses showed homogeneity of effects among the instruments. No significant results were found for the association of genetically determined antithrombin levels with ischemic stroke, CAD or peripheral artery disease (Figure 5A; Figure S5).


Additional analyses using weights derived from deCODE genetics data confirmed the same trends although with nonsignificant results due to weaker instruments (Table S15).

### Protein C

#### Genome-Wide Association Studies

The PC meta-analysis included 16597 EA and 2688 AA participants. After quality control, 72929079 variants were included. All  $\lambda_{GC}$  for individual GWAS were 1.04 or below for autosomal chromosomes (1.18 for X





**Figure 4. Knockdown of GCKR, SNX17, and HP alter antithrombin production in HepG2 cells.**

**A**, Antithrombin secreted into the culture supernatant was detected by immunoblot and quantified by densitometry. **B**, SERPINC1 expression and **(C)** PROC expression were measured by RT-qPCR using the  $\Delta\Delta C_t$  method to compare mRNA abundance and 18S as the reference gene. Bars and error bars indicate mean and SEM; numbers indicate biological replicates; Statistical comparisons were performed by 1-way ANOVA and Šidák's multiple comparisons tests.

chromosome). Additional details about quality control are provided in Table S7 and Supplemental Material.

Manhattan and QQ-plots showing the cross-ancestry meta-analysis results are presented in Figure 3 and Figure S1, respectively. We identified 5 regions associated with PC levels. All loci, located near CELSR2-PRSC1 (1p13.3), PROC (2q14.3), SNX17-GCKR-NRBP1 (2p23.3), MLXIPL-TBL2 (7q11.23), and PROC (20q11.22) genes, have been previously reported to be associated with PC. Coefficients, P values, ancestry stratified EAF and P values, and closest genes are listed in Table 1. Forest plots of significant signals found in the GWAS analysis can be found at Figure S6.

In the conditional analysis at 1p13.3 (CELSR2-PRSC1), 2p23.3 (SNX17-GCKR-NRBP1), and 7q11.23 (MLXIPL-TBL2) loci in the EA population, no additional independent variants were identified (Table S8). Within the PROC locus on chromosome 2, an additional independent variant (rs74392719, MAF=0.01, 300 bases upstream of the lead variant) was identified in the EA population, located within the PROC gene. Finally, an additional independent variant (rs6060300, MAF=0.2, 13 kb upstream of the lead variant) was found in the EA population, intronic to PROC.


No significant heterogeneity was found in the direction or magnitude of beta coefficients for any of the lead variants associated with PC, within or between ancestries. AA and EA population-specific results are shown in Table S9 and Figure S2. The AA population analysis had findings at 2q14.3 (PROC) and 20q11.22 (PROCR); the EA population analysis recapitulated all the candidate loci found in cross-ancestry analysis. The proportion of variance explained by the identified independent variants was 12.7% in EA and 7.4% in AA. The lead variants at the PROC locus (rs11907011 and rs867186) alone explain 9.5% and 9% of the total variance in the EA and AA meta-analyses, respectively. All lead variants from GWAS were replicated in the deCODE data (all  $R < 0.05/11 = 4.5 \times 10^{-3}$ ; Table 1; Table S10).

### Transcriptome-Wide Association Analyses

For PC levels, TWAS (Figure 3B) identified associated genes at 6 loci, matching all loci found in the cross-ancestry and EA GWAS, of which, the most significant based on TWAS z-score values were PSRC1 (chromosome 1, CELSR2-PRSC1 locus), GCKR (chromosome 2, SNX17-GCKR-NRBP1 locus), PROC (chromosome 2), MLXIPL (chromosome 7, MLXIPL-TBL2 locus) and PROC (chromosome 20). Additionally, 3 new associations with PC were found in 1 locus on chromosome 15 for GOLM2, LCMT2 and CATSPER2 genes (Table 1; Table S11).

### Fine Mapping

Fine-mapping results for PC prioritized the PSRC1 gene on chromosome 1, NRBP1 and PROC on chromosome 2 (SNX17-GCKR-NRBP1 and CELSR2-PRSC1 locus,



**Figure 5. Forest plot showing inverse variance weighted mendelian randomization results for multiple outcomes using antithrombin (A) and protein C (B) as exposure.** Squares indicate odds ratio (OR; 95% CI).

respectively), *MLXIPL* and *TBL2* on chromosome 7 (*MLXIPL-TBL2* locus), and *PROCR* on chromosome 20 (Table S12).

#### Functional Validation:

Following the prioritization criteria described on Figure 2, a novel gene identified in the TWAS analysis (*GOLM2*) was selected as a candidate gene for functional validation. Transfection of HepG2 cells with siRNA against the *GOLM2* gene did not alter the cell count (Supplementary Figure S4). PC could not be detected in the media; however, we quantified effects of *GOLM2* silencing on *PROC* RNA expression by RT-qPCR. As expected, control experiments showed that treatment of HepG2 cells with lipofectamine (alone) or siRNA against *SERPINC1* did not significantly alter *PROC* (gene) expression, whereas silencing *PROC* significantly suppressed *PROC* expression (Figure 4C). However, silencing *GOLM2* did not significantly alter *PROC* expression (Figure 4C).

#### MR analysis

For PC, 4 variants were initially selected as genetic instruments for the main analyses, using GWAS summary results (Table S14). After examination of pleiotropic effects, the variant at the *PROCR* gene (rs1799809) was excluded to avoid violations of MR assumptions. Moreover, additional evidence indicates that this variant is strongly associated with several hemostasis and thrombosis phenotypes and has opposite effect directions for venous and arterial thrombosis reflecting distinct pleiotropic biological mechanisms.<sup>17,45</sup> Details of selected genetic instruments can be found in Table S14. There was a significant deleterious effect of genetically determined lower PC levels on VTE and CAD risk (VTE

IWV OR: 0.83 [0.76–0.92]; *P* value: <0.001; CAD IWV OR: 0.92 [0.84–0.99]; *P* value: 0.031; Figure 5B). Sensitivity analyses showed consistent significant associations (Table S15; Figure S5). No significant associations were found between genetically determined PC with peripheral artery disease or ischemic stroke (Figure 5B; Figure S5).

Results using instruments and weights derived from deCODE genetics data replicated a causal association of lower PC on increased VTE risk but could not replicate the effect on CAD (Table S15).

## Protein S

### Genome-Wide Association Study

The PS meta-analysis included 4113 EA individuals in  $PS_{free}$  analyses and 6408 EA individuals in  $PS_{total}$  analyses. A total of 19 791 246 variants were investigated in the analysis of  $PS_{free}$  and 25 365 467 in the analysis of  $PS_{total}$ . All  $\lambda_{GC}$  for individual GWAS were 1.04 or below for autosomal chromosomes (1.19 for X chromosome). Additional details about quality control are provided in Table S7 and Supplemental Material. Manhattan and QQ-plots describing the main results are shown in Figure 2C and 2D and Figure S1 for  $PS_{free}$  and  $PS_{total}$ , and main associated variants are listed in the Table 1. Forest plots of significant signals for  $PS_{free}$  and  $PS_{total}$  can be found in Figure S7.

We identified 1 novel genome-wide significant locus associated with  $PS_{free}$  and  $PS_{total}$  near *ORM1* and *ORM2* genes (9q32) and a known association located near *PROS1* gene (3q11.1) for  $PS_{free}$ . The lead variant at *PROS1* locus (rs121918472, EA  $P=2.04 \times 10^{-16}$ ,  $PS_{free}$  EAF (G)=0.0108) was a missense variant located in the

protein S coding gene *PROS1*. In our analysis, this variant was associated with  $PS_{free}$  level, but genome-wide significance was not observed in  $PS_{total}$  ( $PS_{total} P=2\times 10^{-4}$ ) although there was a consistent direction of effect.

Nominally significant heterogeneity  $P$  values were detected in the *ORM1/ORM2* locus lead variant ( $PS_{total}$  heterogeneity  $P=0.03$ ), indicating minor differences between the 2 measurement methods. No additional independent variants were found with conditional analyses (Table S8). The variance explained by the identified variants in  $PS_{free}$  is 6% of the total variance of  $PS_{free}$  while the variance explained by the unique identified variant in  $PS_{total}$  is 1% of the phenotypic variance for  $PS_{total}$ .

Variants at both loci replicated in the deCODE data (all  $P<0.05/11=4.5\times 10^{-3}$ ; Table 1; Table S10).

### Transcriptome-Wide Association Analyses

$PS_{free}$  TWAS results recapitulated the 2 significant GWAS associations at chromosomes 3 (*PROS1*) and 9 (*ORM2*) and additionally revealed a new association at *MYL7* gene on chromosome 7 (Figure 3; Table S11).

### Fine Mapping

Fine-mapping results did not prioritize any genes for  $PS_{free}$  or  $PS_{total}$ .

### Colocalization

There was a significant colocalization for both PS phenotypes and *ORM2* gene expression in liver (Table S13).

### Functional Validation

Since we were unable to detect PS production in the HepG2 expression system, we were unable to perform functional validation for PS candidates.

### MR Analysis

Given the small proportion of variance explained by the limited number of genetic instruments ( $<3$ ), we did not investigate PS ( $PS_{free}$  and  $PS_{total}$ ) in MR analyses.

## Antithrombin, PC and PS Multiphenotype Analysis

Multiphenotype analyses between antithrombin, PC,  $PS_{free}$ , and  $PS_{total}$  revealed 1 additional novel GWAS association close to the *MAP1A* gene,<sup>46</sup> on chromosome 15 (Table 1), previously found in the PC TWAS (*GOLM2-LCMT2-CATSPER2* locus). The lead variant is a missense variant on the *MAP1A* gene (rs55707100,  $P=1.64\times 10^{-13}$ , EAF EA [T]=0.03, EAF AA [T]=0.0042) that was nominally associated in the GWAS for antithrombin and PC individually (antithrombin  $P=1.04\times 10^{-6}$ , PC  $P=4.76\times 10^{-8}$ ) and was not significantly associated to either of the PS phenotypes ( $PS_{total} P=0.2717$ ,  $PS_{free} P=0.9937$ ). The colocalization results were significant (conditional probability of colocalization  $>0.8$ ) between antithrombin and PC, suggesting the existence of a common variant as regulator of both phenotypes. However,

functional validation by silencing *GOLM2* gene in this locus did not significantly alter expression of *PROC* or *SERPINC1* in HepG2 cells (Figure 4B and 4C), suggesting any potential co-regulatory effect is not mediated in the production of these proteins.

## DISCUSSION

We performed GWAS for 3 natural anticoagulant hemostasis phenotypes (antithrombin, PC, and PS [ $PS_{total}$  and  $PS_{free}$ ]) using larger sample sizes and better imputation panels than previously reported and detected 4 novel associations: 3 loci for antithrombin (*SNX17-GCKR-NRBP1*, *MLXIPL-BAZ1B-BCL7B*, and *HP-TXNL4B*) and 1 locus for PS (*ORM1-ORM2*). For 3 genes within the newly associated loci with antithrombin (*SNX17*, *GCKR*, and *HP*), in vitro gene silencing in liver-derived cells provided functional evidence. Using TWAS methods, we detected 3 additional novel associations that did not reach significance in individual GWAS: *FCGRT* for antithrombin; *GOLM2* for PC; and *MYL7* for PS. Using MR, we also identified a causal relationship of antithrombin and PC levels with VTE, and of PC levels with CAD. This investigation elucidated genetic regulation of the anticoagulant pathway and provides new information that could identify therapeutic targets in VTE prevention or treatment.

Additionally, we replicated 7 known loci<sup>5,13,15-17</sup> for PC; and 1 for PS.<sup>7</sup> Two of the known PC loci, also had novel associations with antithrombin, demonstrating some genetic overlap between different anticoagulant proteins. This was also reflected in the multiphenotype analysis results.

## Characterization of Novel Loci

### Antithrombin-Associated Loci

More than 45 rare variants within the *SERPINC1* gene have already been described using non-GWAS approaches.<sup>47</sup> Our lead variant, rs2227624, is a known missense variant causing a Val to Glu amino-acid substitution that leads to antithrombin deficiency<sup>48,49</sup> and increases risk of VTE.<sup>50</sup>

On chromosome 2, lead variants in locus *SNX17-GCKR-NRBP1* differed by ancestry. In the cross-ancestry analysis, rs4665972 was in an intronic region of *SNX17* whereas, in the EA-specific analysis, the lead variant (rs11127048) was located in an intergenic region between the *SNX17* and *GCKR* genes. Neither rs4665972 nor rs11127048 were significant in AA population suggesting that these variants are tagging an association within a large LD block in EA population. Consistent with this observation, conditional results indicate that the lead variant (rs4665972) is the only independent variant on this locus. Given limited power in the AA-specific analysis, we could not refine the region

with AA data (Figure S12). Functional validation in liver-derived cells suggests that *SNX17* positively, and *GCKR* negatively, alter plasma antithrombin levels via effects on *SERPINC1* expression.

*SNX17* is a regulator of LDL (low-density lipoprotein) receptors<sup>51</sup> and has not been previously associated to antithrombin levels but has been associated with CAD.<sup>52,53</sup> *GCKR* is a highly pleiotropic gene that has been found significantly associated to multiple phenotypes.<sup>18</sup> We and others have also reported genetic associations with several hemostatic factors, including PC,<sup>14,15</sup> Factor VII (FVII),<sup>54</sup> Factor XI (FXI)<sup>55</sup> and CRP (C-reactive protein)<sup>56,57</sup> in previous GWAS meta-analyses. In previous candidate gene studies,<sup>58–60</sup> variant rs1260326 in *GCKR* was found to be related to multiple cardiometabolic traits, including total and LDL cholesterol, fasting plasma glucose, liver fat content, and metabolic syndrome, suggesting that *GCKR* might act as a broad regulator of hepatocyte function.<sup>61</sup>

On chromosome 7, the lead variant (rs13244268) was located in an intronic region of *BAZ1B* gene and was only significant in the EA population. This gene has been previously associated with PC<sup>14,15</sup> and in our PC meta-analysis, but not with antithrombin. rs13244268 was also found significant in bivariate and univariate GWAS of CRP and high-density lipoprotein.<sup>62</sup> TWAS results confirmed an association between *BCL7B* and *MLXIPL* genes in this locus and antithrombin levels. Given the differences in LD blocks observed for this region in different populations, we sought to confirm the most plausible candidate genes in this locus with in vitro silencing studies in liver cells. Within the 3 candidate genes in the region (*BAZ1B*, *MLXIPL* and *BCL7B*), *BAZ1B* presented low expression in liver, and *MLXIPL* and *BCL7B* were not prioritized for functional validation due to biological implausibility. Since no candidates in this region passed preselection for functional work, the elucidation of this locus and its role on antithrombin regulation warrants further investigation.

The lead variant on *HP-TXNL4B* locus (rs5471) is in an intronic region of the *TXNL4B* gene and 5' UTR of the *HP* gene and was only significant in the AA population. Colocalization results performed using cross-ancestry data suggested the existence of a common regulatory variant between *HP* gene expression and antithrombin levels in liver and whole blood, and suggested that higher expression of *HP* in liver and blood were associated with higher levels of antithrombin in plasma. In the same direction, functional validation in HepG2 cells suggested a significant reduction of antithrombin levels upon *HP* silencing through as-yet unidentified post-transcriptional mechanism. *HP* codes for haptoglobin (Hp), which serves as a binding protein of hemoglobin, and affects the release of hemoglobin from red blood cells.<sup>63</sup> Its phenotype Hp2-2 was identified as a potential regulator of inflammation and reverse cholesterol transportation

and has been suggested to have higher prevalence in patients with VTE.<sup>64–66</sup> Overall, previous evidence suggests a potential role of Hp in the inflammation-induced thrombosis, and our results suggest *HP* is a potential direct regulator of antithrombin production.

Finally, TWAS results suggested a novel locus associated to antithrombin levels on the *FCGRT* gene. Colocalization results suggested the existence of a common regulatory variant between antithrombin levels and the expression of *FCGRT*, *RPS11* and *RCN3* in the aorta, tibial artery, and whole blood. In GWAS analysis, rs111981233 (intronic to *FCGRT*) nearly reached genome-wide significance levels. *FCGRT* encodes a receptor that binds immunoglobulin G and transfers immunoglobulin G antibodies from mother to fetus across the placenta<sup>67</sup> and previous studies demonstrate that *FCGRT* is also expressed in the liver.<sup>68</sup> Additional work is needed to further elucidate the role of this gene in antithrombin regulation.

### Protein C-Associated Loci

We found 5 loci associated with PC in the present GWAS meta-analysis, all of which had been previously described. In addition, 3 genes (*GOLM2*, *LCMT2*, and *CATSPER2*) were associated in a novel locus on chromosome 15 in the TWAS analysis. *GOLM2*, the only gene with significant expression in the liver, encodes for a transmembrane protein predicted to colocalize in the Golgi apparatus with no known function; Interestingly, a variant near this locus was significant in the PC-antithrombin multiphenotype GWAS analysis, and colocalization results suggested the existence of a common variant between antithrombin and PC. Our functional validation suggest *GOLM2* does not regulate PC transcription, although our experiments did not allow us to assess a post-transcriptional role of *GOLM2* on PC, or a role in clearance.

### PS-Associated Loci

For PS, genome-wide associations found at the *ORM1-ORM2* locus represented novel findings for both  $PS_{free}$  and  $PS_{total}$ , and colocalization analysis suggests the existence of a common regulatory variant between  $PS_{free}$  and  $PS_{total}$  levels and *ORM2* expression in liver. *ORM1* is responsible for encoding acute phase plasma protein orosomucoid (ORM, also known as AGP [ $\alpha$ 1-acid-glycoprotein]), which is increased with acute inflammation.<sup>69</sup> Previous genetic results suggested that *ORM1* was associated with thrombin generation potential,<sup>70</sup> and the discovery was further confirmed with in vitro experiments. *ORM1* has also been associated with cell-free DNA levels in plasma, a surrogate marker of neutrophil extracellular traps that contribute to immunothrombosis.<sup>71</sup> Moreover, AGPs encoded by the *ORM1* and *ORM2* genes strongly bind to the vitamin K antagonist warfarin that reaches circulation, suggesting that these genes could be relevant in regulating the response to oral anticoagulation.<sup>72</sup> Supporting this hypothesis, *ORM1*, *ORM2*, and *PROC* were nominally associated with warfarin dose requirement in

a study of candidate gene analysis with 201 patients.<sup>73</sup> This is interesting, since it is widely known that one of the challenges in oral anticoagulation is the wide variation in response among patients.<sup>74</sup> Confirming novel genomic regulators of anticoagulant response could help explain the mechanisms of action of these drugs and move toward a personalized treatment based on genomic background.

*MYL7*, associated with PS levels in the TWAS analyses, is the gene coding for myosin light chain 7 protein and was previously related to calcium ion binding activity.<sup>75,76</sup> Variants in this gene have been associated with fasting glucose levels and type II diabetes<sup>77,78</sup> probably for their proximity to the *glucokinase (GCK)* gene, which lies 1.9 kb upstream of *MYL7*, and is essential for producing glucose-6-phosphate.

### Implication for Disease Outcomes

Several of the identified loci have been previously associated with cardiovascular disease outcomes (Table S16).

The present MR results confirm a causal relationship between genetically determined plasma levels of antithrombin and PC with VTE events, and for PC with CAD outcomes. Specifically, we observed a 19% VTE risk increase per 1 SD decrease in antithrombin plasma levels, a 20% VTE risk increase per 1 SD decrease of PC plasma levels, and a 9% CAD risk increase per 1 SD decrease in PC plasma levels. Our findings of a causal relationship of antithrombin and PC with VTE agree with previous epidemiological studies that report an increased VTE risk in individuals with deficiencies of these anticoagulants.<sup>4,79,80</sup> The causal relationship between PC and CAD was also reported in previous epidemiological and MR studies.<sup>81,82</sup> Overall, these results support previous data suggesting that antithrombin and PC are relevant proteins that regulate the risk of VTE, confirmed the causal association between PC levels and CAD, and corroborated that intervention in the anticoagulant system could be considered for VTE or CAD prevention.<sup>83,84</sup>

### Strengths and Limitations

A major strength of this study is in the modestly large sample size, including around 30 000 individuals, compared with more limited studies in the previous discovery efforts. Additionally, the TOPMed (Trans-Omics for Precision Medicine) imputation panel, provides better imputation quality for low-frequency variants compared with previous panels, which increases our power to detect rare variation. However, the present study was not designed to provide a detailed evaluation of rare variation within coding genes, and some rare variants within these genes were excluded from the analyses if they were present in <2 studies. Larger studies combined with whole genome sequencing data will help identify novel

rare (familial) associations for these phenotypes and may provide better instruments that will improve the power for MR studies.

Inclusion of AA individuals has allowed the identification of novel associated loci for antithrombin in this population. We were not able to perform discovery in other ancestry populations since measures of phenotypes and genotypes were not available to us. Investing in these measures in other ancestry groups may increase the number of discoveries and provide more global insights. There is a recent debate<sup>85,86</sup> on transferability of results from GWAS studies to non-European populations, given the overwhelming majority of GWAS results in EA populations for most phenotypes. Although our sample was predominantly of EA, we were able to observe differences in LD blocks between EA and AA ancestry groups, which allowed us to detect novel associations in variants with lower frequency in the EA population, and to refine loci where the linkage blocks differed between ancestries. Ancestry-differences in genetic studies are usually not due to environmental or social factors when populations stratification is properly accounted for as these factors cannot confound genetic associations. However, some of the follow-up methods (TWAS, approximate conditional analyses) depend on population reference panels and were limited to the EA population.

Additionally, sex-stratified analyses were not included in this work and may have provided insights into possible sex-specific regulators of natural anticoagulants.

Finally, to reduce the risk of false positives, we used a stringent significance threshold ( $5 \times 10^{-9}$ ), sought replication of the main findings in an external study, and provided additional post-GWAS evidence for our novel findings. We included functional validation using *in vitro* silencing to provide evidence for causality of candidate genes and help understand the biological mechanism. We think this strengthens the credibility of our results. However, liver cell-derived expression system is only able to assess effects of candidate genes on synthetic mechanisms (eg, transcription, translation) and is not able to assess potential effects on protein stability and/or clearance. Thus, genes that did not demonstrate an effect, as well as genes that were not selected for testing in this system, could regulate circulating anticoagulant protein expression via synthesis-independent mechanisms.

### Summary

Using cross-ancestry GWAS and TWAS methods, we report 7 novel associations for antithrombin, PC, and PS plasma levels: 4 novel loci regulating antithrombin plasma levels, 2 novel loci regulating PS plasma levels, and 1 novel locus regulating PC plasma levels. Post-GWAS analyses and functional work suggest both *SNX17* and *GCKR* are regulators of antithrombin on the chromosome 2 locus and validate an AA-specific *HP* gene locus. MR

analyses provided evidence implicating low antithrombin levels in VTE risk and low PC levels in VTE and CAD risk. Overall, our findings identified novel pathways regulating the main anticoagulant proteins in hemostasis and strengthen their implication on disease outcomes.

## ARTICLE INFORMATION

Received August 25, 2022; accepted April 13, 2023.

### Affiliations

Cardiovascular Division, Department of Medicine, University of Minnesota, MN (Y.J.). Unit of genomics of Complex Disease, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Barcelona, Spain (G.T.-S., N.-Q.L., A.M.-P., J.C.S., J.M.S., M.S.-L.). Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill (L.A.H., K.K., D.A.D., A.S.W.). Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston (A.B., M.R.B., A.C.M., P.S.d.V.). Department of Medicine, University of Washington (J.A.B., K.L.W.). Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle (C.M.S.). C2VN, INSERM, INRAE, Aix Marseille Univ, France (P.S., P.-E.M.). Laboratory of Haematology, La Timone Hospital, France (P.S., P.-E.M.). SYNLAB MVZ für Humangenetik Mannheim, Germany (M.E.K.). Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Germany (M.E.K., G.E.D., A.P.M., W.M.). Institute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Italy (D.B.E., M.G., C.F., A.A.H.). Department of Human Genetics, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor (A.B.O.). Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, MN (W.T., J.S.P.). Unit of Thrombosis and Hemostasis, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.L., J.C.S.). Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington (R.P.T.). Centre National de Recherche en Génétique Humaine, CEA, France (J.-F.D.). Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, France (J.-F.D.). Laboratory of Excellence on Medical Genomics (GenMed), France (J.-F.D., D.-A.T.). The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, CA (K.D.T.). INSERM UMR 1219, Bordeaux Population Health Research Center, France (D.-A.T.). Institute of Nutritional Sciences, Friedrich Schiller University Jena, Germany (A.P.M.). Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany (A.P.M.). Department of Clinical Epidemiology, Leiden University Medical Center, the Netherlands (F.R.R.). Larner College of Medicine, University of Vermont, Burlington (M.C.). Synlab Academy, Synlab Holding Deutschland GmbH, Germany (W.M.). Department of Pediatrics, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor (K.C.D.). National Heart Lung and Blood Institute, Division of Intramural Research, Population Sciences Branch, The Framingham Heart Study, MA (A.D.J.). Department of Epidemiology, University of Washington, Seattle (N.L.S.). Kaiser Permanente Washington Health Research Institute (N.L.S.). Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, WA (N.L.S.). Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden (M.S.-L.).

### Acknowledgments

We would also like to thank the MEGASTROKE Consortium, DeCODE genetics, the International Network Against Venous Thrombosis (INVENT) Consortium, CARDIoGRAMplusC4D Consortium and Million Veterans Program for making their data publicly available. The MEGASTROKE project received funding from sources specified at <https://www.megastroke.org/acknowledgements.html>. Appendix 1 contains a list with all authors that contributed to MEGASTROKE project (<https://www.megastroke.org/authors.html>). Data on coronary artery disease has been contributed by CARDIoGRAMplusC4D investigators and have been downloaded from <http://www.cardiogramplusc4d.org>. Data from DeCODE genetics was accessed through DeCode genetics web page at [decode.com](http://decode.com). VTE and peripheral artery disease data from de Million Veteran Program were accessed through dbGAPs (phs001672 v7p1).

### Sources of Funding

This study is supported in part by the National Heart, Lung, and Blood Institute grant HL134894, HL139553, HL126974, and HL141291-S1A; infrastructure for the CHARGE Consortium is supported in part by HL105756. The views

expressed in this article are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the US Department of Health and Human Services. G. Temprano-Sagrera is supported by the *Pla Estratègic de Recerca i Innovació en Salut (PERIS)* grant from the Catalan Department of Health for junior research personnel (SLT017/20/000100). P.S. de Vries is supported by American Heart Association grant 17POST33350042. M. Sabater-Lleal is supported by a *Miguel Servet* contract from the Instituto de Salud Carlos III (ISCIII) Spanish Health Institute (CP17/00142) and co-financed by the European Social Fund, and acknowledges funding from the CERCA Program/Generalitat de Catalunya. Sources of funding for the specific studies can be found in the Supplemental Material.

### Disclosures

None.

### Supplemental Material

Supplemental Methods

Cohort-Specific Information

Tables S1–S16

Figures S1–S8

Funding and Acknowledgements from Specific Cohorts

Major Resources Table

References 87–115

## REFERENCES

1. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. *N Engl J Med*. 1983;309:340–344. doi: 10.1056/NEJM198308113090604
2. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. *J Clin Invest*. 1981;68:1370–1373. doi: 10.1172/jci110385
3. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. *Blood*. 1984;64:1297–1300.
4. Folsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. *Arterioscler Thromb Vasc Biol*. 2002;22:1018–1022. doi: 10.1161/01.atv.0000017470.08363.ab
5. Antón AI, Teruel R, Corral J, Miñano A, Martínez-Martínez I, Ordóñez A, Vicente V, Sánchez-Vega B. Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels. *Haematologica*. 2009;94:589–592. doi: 10.3324/haematol.2008.000604
6. Shamsher MK, Chuzhanova NA, Friedman B, Scopes DA, Alhaq A, Millar DS, Cooper DN, Berg LP. Identification of an intronic regulatory element in the human protein C (PROC) gene. *Hum Genet*. 2000;107:458–465. doi: 10.1007/s004390000391
7. Leroy-Matheron C, Duchemin J, Levent M, Gouault-Heilmann M. Genetic modulation of plasma protein S levels by two frequent dimorphisms in the PROS1 gene. *Thromb Haemost*. 1999;82:1088–1092.
8. El-Galaly TC, Severinsen MT, Overvad K, Steffensen R, Vistisen AK, Tjønneland A, Kristensen SR. Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study. *Br J Haematol*. 2013;160:838–841. doi: 10.1111/bjh.12132
9. Grundy CB, Chisholm M, Kakkar VV, Cooper DN. A novel homozygous missense mutation in the protein C (PROC) gene causing recurrent venous thrombosis. *Hum Genet*. 1992;89:683–684. doi: 10.1007/BF00221963
10. Millar DS, Grundy CB, Bignell P, Mitchell DC, Corden D, Woods P, Kakkar VV, Cooper DN. A novel nonsense mutation in the protein C (PROC) gene (Trp-29→term) causing recurrent venous thrombosis. *Hum Genet*. 1993;91:196. doi: 10.1007/BF00222726
11. Wu D, Zhong Z, Chen Y, Ding H, Yang M, Lian N, Huang Z, Zhang Q, Zhao J, Deng C. Analysis of PROC and PROS1 single nucleotide polymorphisms in a thrombophilia family. *Clin Respir J*. 2019;13:530–537. doi: 10.1111/crj.13055
12. de la Morena-Barrio ME, Buil A, Antón AI, Martínez-Martínez I, Miñano A, Gutiérrez-Gallego R, Navarro-Fernández J, Aguila S, Souto JC, Vicente V, et al. Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional glycosyltransferase, in the secretion of proteins?. *PLoS One*. 2013;8:e64998. doi: 10.1371/journal.pone.0064998
13. Oudot-Mellakh T, Cohen W, Germain M, Saut N, Kallel C, Zelenika D, Lathrop M, Tréguët DA, Morange PE. Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. *Br J Haematol*. 2012;157:230–239. doi: 10.1111/j.1365-2141.2011.09025.x

14. Tang W, Basu S, Kong X, Pankow JS, Aleksic N, Tan A, Cushman M, Boerwinkle E, Folsom AR. Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study. *Blood*. 2010;116:5032–5036. doi: 10.1182/blood-2010-05-283739
15. Pankow JS, Tang W, Pankratz N, Guan W, Weng LC, Cushman M, Boerwinkle E, Folsom AR. Identification of genetic variants linking Protein C and lipoprotein metabolism: the ARIC study (Atherosclerosis Risk in Communities). *Arterioscler Thromb Vasc Biol*. 2017;37:589–597. doi: 10.1161/ATVBAHA.116.308109
16. Munir MS, Weng LC, Tang W, Basu S, Pankow JS, Matijevic N, Cushman M, Boerwinkle E, Folsom AR. Genetic markers associated with plasma protein C level in African Americans: the atherosclerosis risk in communities (ARIC) study. *Genet Epidemiol*. 2014;38:709–713. doi: 10.1002/gepi.21868
17. Athanasiadis G, Buil A, Souto JC, Borrell M, López S, Martínez-Perez A, Lathrop M, Fontcuberta J, Almasly L, Soria JM. A genome-wide association study of the Protein C anticoagulant pathway. *PLoS One*. 2011;6:e29168. doi: 10.1371/journal.pone.0029168
18. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrismisdottir EL, Gunnarsdottir K, Helgason A, Oddsson A, Halldorsson BV, et al. Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet*. 2021;53:1712–1721. doi: 10.1038/s41588-021-00978-w
19. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JJ, Uitterlinden AG, Harris TB, Witteman JC, Boerwinkle E; CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet*. 2009;2:73–80. doi: 10.1161/CIRCGENETICS.108.829747
20. Investigators A. The Atherosclerosis risk in COMMUNIT (ARIC) study: design and objectives. *Am J Epidemiol*. 1989;129:687–702.
21. Pattaro C, Gögele M, Mascalzoni D, Melotti R, Schwienbacher C, De Grandi A, Foco L, D'Elia Y, Linder B, Fuchsberger C, et al. The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. *J Transl Med*. 2015;13:348. doi: 10.1186/s12967-015-0704-9
22. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol*. 1991;1:263–276. doi: 10.1016/1047-2797(91)90005-w
23. Desch K, Li J, Kim S, Laventhal N, Metzger K, Siemieniak D, Ginsburg D. Analysis of informed consent document utilization in a minimal-risk genetic study. *Ann Intern Med*. 2011;155:316–322. doi: 10.7326/0003-4819-155-5-201109060-00009
24. Souto JC, Almasly L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, Coll I, Felices R, Stone W, Fontcuberta J, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. *Am J Hum Genet*. 2000;67:1452–1459. doi: 10.1086/316903
25. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. *JAMA*. 1995;274:620–625.
26. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. *Eur Heart J*. 2010;31:1237–1247. doi: 10.1093/eurheartj/ehq019
27. Antoni G, Oudot-Mellakh T, Dimitromanolakis A, Germain M, Cohen W, Wells P, Lathrop M, Gagnon F, Morange PE, Tregouet DA. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. *BMC Med Genet*. 2011;12:102. doi: 10.1186/1471-2350-12-102
28. Vázquez-Santiago M, Vilalta N, Cuevas B, Murillo J, Llobet D, Macho R, Pujol-Moix N, Carrasco M, Mateo J, Fontcuberta J, et al. Short closure time values in PFA-100® are related to venous thrombotic risk. Results from the RETROVE Study. *Thromb Res*. 2018;169:57–63. doi: 10.1016/j.thromres.2018.07.012
29. Mills JL, Carter TC, Scott JM, Troendle JF, Gibney ER, Shane B, Kirke PN, Ueland PM, Brody LC, Molloy AM. Do high blood folate concentrations exacerbate metabolic abnormalities in people with low vitamin B-12 status? *Am J Clin Nutr*. 2011;94:495–500. doi: 10.3945/ajcn.111.014621
30. Pattaro C, Gögele M, Mascalzoni D, Melotti R, Schwienbacher C, De Grandi A, Foco L, D'Elia Y, Linder B, Fuchsberger C, et al. The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. *J Transl Med*. 2015;13:1–16.
31. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. *Arch Intern Med*. 1994;154:1333–1339.
32. Desch KC, Ozel AB, Siemieniak D, Kalish Y, Shavit JA, Thornburg CD, Sharathkumar AA, McHugh CP, Laurie CC, Crenshaw A, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. *Proc Natl Acad Sci U S A*. 2013;110:588–593. doi: 10.1073/pnas.1219885110
33. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, Jain D, Argos M, Arnett DK, Avery C, et al; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet*. 2019;15:e1008500. doi: 10.1371/journal.pgen.1008500
34. Winkler TW, Day FR, Croteau-Chonka DC, Wood AR, Locke AE, Mägi R, Ferreira T, Fall T, Graff M, Justice AE, et al; Genetic Investigation of Anthropometric Traits (GIANT) Consortium. Quality control and conduct of genome-wide association meta-analyses. *Nat Protoc*. 2014;9:1192–1212. doi: 10.1038/nprot.2014.071
35. Pulit SL, de With SA, de Bakker PI. Resetting the bar: statistical significance in whole-genome sequencing-based association studies of global populations. *Genet Epidemiol*. 2017;41:145–151. doi: 10.1002/gepi.22032
36. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, Torstenson ES, Shah KP, Garcia T, Edwards TL, et al; GTEx Consortium. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun*. 2018;9:1825. doi: 10.1038/s41467-018-03621-1
37. Barbeira AN, Pividori M, Zheng J, Wheeler HE, Nicolae DL, Im HK. Integrating predicted transcriptome from multiple tissues improves association detection. *PLoS Genet*. 2019;15:e1007889. doi: 10.1371/journal.pgen.1007889
38. Ray D, Boehnke M. Methods for meta-analysis of multiple traits using GWAS summary statistics. *Genet Epidemiol*. 2018;42:134–145. doi: 10.1002/gepi.22105
39. Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, Bollen KA, Brembs B, Brown L, Camerer C, et al. Redefine statistical significance. *Nat Hum Behav*. 2018;2:6–10. doi: 10.1038/s41562-017-0189-z
40. Lindström S, Wang L, Smith EN, Gordon W, van Hylckama Vlieg A, de Andrade M, Brody JA, Pattee JW, Haessler J, Brumpton BM, et al; Million Veteran Program. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. *Blood*. 2019;134:1645–1657. doi: 10.1182/blood.2019000435
41. Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, et al; INVENT Consortium. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. *Nat Genet*. 2019;51:1574–1579. doi: 10.1038/s41588-019-0519-3
42. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q, Huffman JE, Natarajan P, et al; VA Million Veteran Program. Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nat Med*. 2019;25:1274–1279. doi: 10.1038/s41591-019-0492-5
43. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015;47:1121–1130. doi: 10.1038/ng.3396
44. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, et al; AFGen Consortium. Multiethnic genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. 2018;50:524–537. doi: 10.1038/s41588-018-0058-3
45. Stacey D, Chen L, Stanczyk FJ, Howson JM, Mason AM, Burgess S, MacDonald S, Langdown J, McKinney H, Downes K. Elucidating mechanisms of genetic cross-disease associations at the PROCRA vascular disease locus. *Nat Commun*. 2022;13:1–15.
46. Temprano-Sagrera G, Sitlani CM, Bone WP, Martin-Bornez M, Voight BF, Morrison AC, Damrauer SM, de Vries PS, Smith NL, Sabater-Lleal M. Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. *J Thromb Haemost*. 2022;20:1331–1349. doi: 10.1111/jth.15698
47. Manderstedt E, Lind-Hallén C, Hallén C, Elf J, Svensson PJ, Dahlbäck B, Engström G, Melander O, Baras A, Lotta LA, et al; Regeneron Genetics Center 4 [Link]. Classic thrombophilias and thrombotic risk among middle-aged and older adults: a population-based cohort study. *J Am Heart Assoc*. 2022;11:e023018. doi: 10.1161/JAHA.121.023018
48. Dürr C, Hinney A, Luckenbach C, Kömpf J, Ritter H. Genetic studies of antithrombin III with IEF and ASO hybridization. *Hum Genet*. 1992;90:457–459. doi: 10.1007/BF00220477

49. Daly M, O'Meara A, Hallinan FM. Identification and characterization of a new antithrombin III familial variant (AT Dublin) with possible increased frequency in children with cancer. *Br J Haematol*. 1987;65:457–462. doi: 10.1111/j.1365-2141.1987.tb04150.x
50. Downes K, Megy K, Duarte D, Vries M, Gebhart J, Hofer S, Shamardina O, Deevi SVV, Stephens J, Mapeta R, et al; NIH BioResource. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. *Blood*. 2019;134:2082–2091. doi: 10.1182/blood.2018891192
51. Stockinger W, Sailler B, Strasser V, Recheis B, Fasching D, Kahr L, Schneider WJ, Nimpf J. The PX-domain protein SNX17 interacts with members of the LDL receptor family and modulates endocytosis of the LDL receptor. *EMBO J*. 2002;21:4259–4267. doi: 10.1093/emboj/cdf435
52. Zhao D, Li X, Liang H, Zheng N, Pan Z, Zhou Y, Liu X, Qian M, Xu B, Zhang Y, et al. SNX17 produces anti-arrhythmic effects by preserving functional SERCA2a protein in myocardial infarction. *Int J Cardiol*. 2018;272:298–305. doi: 10.1016/j.ijcard.2018.07.025
53. Yang J, Villar VAM, Rozyyev S, Jose PA, Zeng C. The emerging role of sorting nexins in cardiovascular diseases. *Clin Sci (Lond)*. 2019;133:723–737. doi: 10.1042/CS20190034
54. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Lleal M, Bis JC, et al; Wellcome Trust Case Control Consortium; Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. *Circulation*. 2010;121:1382–1392. doi: 10.1161/CIRCULATIONAHA.109.869156
55. Sennblad B, Basu S, Mazur J, Suchon P, Martinez-Perez A, van Hylckama Vlieg A, Truong V, Li Y, Gådin JR, Tang W, et al. Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels. *Hum Mol Genet*. 2017;26:637–649. doi: 10.1093/hmg/ddw401
56. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. *Thromb Haemost*. 2009;102:615–619. doi: 10.1160/TH09-04-0274
57. Ellis J, Lange EM, Li J, Dupuis J, Baumert J, Walston JD, Keating BJ, Durda P, Fox ER, Palmer CD, et al. Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. *Hum Genet*. 2014;133:985–995. doi: 10.1007/s00439-014-1439-z
58. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. *Hepatology*. 2012;55:781–789. doi: 10.1002/hep.24806
59. Petit JM, Masson D, Guiu B, Rollet F, Duvillard L, Bouillet B, Brindisi MC, Buffier P, Hillon P, Cerceuil JP, et al. GCKR polymorphism influences liver fat content in patients with type 2 diabetes. *Acta Diabetol*. 2016;53:237–242. doi: 10.1007/s00592-015-0766-4
60. Yeh KH, Hsu LA, Teng MS, Wu S, Chou HH, Ko YL. Pleiotropic effects of common and rare GCKR exonic mutations on cardiometabolic traits. *Genes (Basel)*. 2022;13:491. doi: 10.3390/genes13030491
61. Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. *Endocr J*. 2014;61:683–689.
62. Ligthart S, Vaez A, Vösa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, et al; LifeLines Cohort Study. Genome analyses of >200,000 individuals identify 58 Loci for chronic inflammation and highlight pathways that link inflammation and complex disorders. *Am J Hum Genet*. 2018;103:691–706. doi: 10.1016/j.ajhg.2018.09.009
63. Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure of haptoglobin and the haptoglobin-hemoglobin complex by electron microscopy. *J Mol Biol*. 1984;174:319–341. doi: 10.1016/0022-2836(84)90341-3
64. Landis RC, Philippidis P, Domin J, Boyle JJ, Haskard DO. Haptoglobin genotype-dependent anti-inflammatory signaling in CD163(+) macrophages. *Int J Inflam*. 2013;2013:980327. doi: 10.1155/2013/980327
65. Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. *Circ Res*. 2006;99:1419–1425. doi: 10.1161/01.RES.0000251741.65179.56
66. Vormittag R, Vukovich T, Mannhalter C, Minar E, Schönauer V, Bialonczyk C, Hirschl M, Pabinger I. Haptoglobin phenotype 2-2 as a potentially new risk factor for spontaneous venous thromboembolism. *Haematologica*. 2005;90:1557–1561.
67. Mikulska JE, Pablo L, Canel J, Simister NE. Cloning and analysis of the gene encoding the human neonatal Fc receptor. *Eur J Immunogenet*. 2000;27:231–240. doi: 10.1046/j.1365-2370.2000.00225.x
68. Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, et al. Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. *Proc Natl Acad Sci U S A*. 2017;114:E2862–E2871. doi: 10.1073/pnas.1618291114
69. Dente L, Pizza MG, Metspalu A, Cortese R. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. *EMBO J*. 1987;6:2289–2296. doi: 10.1002/j.1460-2075.1987.tb02503.x
70. Rocanin-Arjo A, Cohen W, Carcaillon L, Frère C, Saut N, Letenneur L, Alhenc-Gelas M, Dupuy AM, Bertrand M, Alessi MC, et al; CardioGenics Consortium. A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. *Blood*. 2014;123:777–785. doi: 10.1182/blood-2013-10-529628
71. Lopez S, Martinez-Perez A, Rodriguez-Rius A, Viñuela A, Brown AA, Martin-Fernandez L, Vilalta N, Arús M, Panousis NI, Buil A, et al. Integrated GWAS and gene expression suggest ORM1 as a potential regulator of plasma levels of cell-free DNA and thrombosis risk. *Thromb Haemost*. 2022;122:1027–1039. doi: 10.1055/s-0041-1742169
72. Otagiri M, Maruyama T, Imai T, Suenaga A, Imamura Y. A comparative study of the interaction of warfarin with human alpha 1-acid glycoprotein and human albumin. *J Pharm Pharmacol*. 1987;39:416–420. doi: 10.1111/j.2042-7158.1987.tb03412.x
73. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. *Hum Genet*. 2007;121:23–34. doi: 10.1007/s00439-006-0260-8
74. Bourgeois S, Jorgensen A, Zhang EJ, Hanson A, Gillman MS, Bumpstead S, Toh CH, Williamson P, Daly AK, Kamali F, et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. *Genome Med*. 2016;8:2. doi: 10.1186/s13073-015-0255-y
75. Morano I, Hofmann F, Zimmer M, Rüegg JC. The influence of P-light chain phosphorylation by myosin light chain kinase on the calcium sensitivity of chemically skinned heart fibres. *FEBS Lett*. 1985;189:221–224. doi: 10.1016/0014-5793(85)81027-9
76. Himpens B, Matthijs G, Somlyo AV, Butler TM, Somlyo AP. Cytoplasmic free calcium, myosin light chain phosphorylation, and force in phasic and tonic smooth muscle. *J Gen Physiol*. 1988;92:713–729. doi: 10.1085/jgp.92.6.713
77. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, Huffman JE, Assimes TL, Lorenz K, Zhu X, et al; HPAP Consortium. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet*. 2020;52:680–691. doi: 10.1038/s41588-020-0637-y
78. Chung RH, Chiu YF, Wang WC, Hwu CM, Hung YJ, Lee IT, Chuang LM, Quartermost T, Rotter JI, Chen YI, et al. Multi-omics analysis identifies CpGs near G6PC2 mediating the effects of genetic variants on fasting glucose. *Diabetologia*. 2021;64:1613–1625. doi: 10.1007/s00125-021-05449-9
79. Mahmoodi BK, Brouwer JL, Ten Kate MK, Lijfering WM, Veeger NJ, Mulder AB, Kluijn-Nelemans HC, Van Der Meer J. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. *J Thromb Haemost*. 2010;8:1193–1200. doi: 10.1111/j.1538-7836.2010.03840.x
80. Pabinger I, Kyrle PA, Heisteringer M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. *Thromb Haemost*. 1994;71:441–445.
81. Schooling CM, Zhong Y. Plasma levels of the anti-coagulation protein C and the risk of ischaemic heart disease. A Mendelian randomisation study. *Thromb Haemost*. 2017;117:262–268. doi: 10.1160/TH16-07-0518
82. O'Connor NT, Broekmans AW, Bertina RM. Protein C values in coronary artery disease. *Br Med J (Clin Res Ed)*. 1984;289:1192. doi: 10.1136/bmj.289.6453.1192
83. Wessler S, Gaston LW. Anticoagulant therapy in coronary artery disease. *Circulation*. 1966;34:856–864. doi: 10.1161/01.cir.34.5.856
84. Wilbur J, Shian B. Deep venous thrombosis and pulmonary embolism: current therapy. *Am Fam Physician*. 2017;95:295–302.
85. Kuchenbaecker K, Telkar N, Reiker T, Walters RG, Lin K, Eriksson A, Gurdasani D, Gilly A, Southam L, Tsafantakis E, et al; Understanding Society Scientific Group. The transferability of lipid loci across African, Asian and European cohorts. *Nat Commun*. 2019;10:4330. doi: 10.1038/s41467-019-12026-7



86. Evans DS, Avery CL, Nalls MA, Li G, Barnard J, Smith EN, Tanaka T, Butler AM, Buxbaum SG, Alonso A, et al; CHARGE QRS Consortium. Fine-mapping, novel loci identification, and SNP association transferability in a genome-wide association study of QRS duration in African Americans. *Hum Mol Genet.* 2016;25:4350–4368. doi: 10.1093/hmg/ddw284
87. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010;26:2190–2191. doi: 10.1093/bioinformatics/btq340
88. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, Martin NG, Montgomery GW, Weedon MN, Loos RJ, et al; Genetic Investigation of ANthropometric Traits (GIANT) Consortium. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet.* 2012;44:369–75, S1. doi: 10.1038/ng.2213
89. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet.* 2011;88:76–82. doi: 10.1016/j.ajhg.2010.11.011
90. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature.* 2015;526:68–74. doi: 10.1038/nature15393
91. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N. The genotype-tissue expression (GTEx) project. *Nat Genet.* 2013;45:580–585.
92. Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, Wang G, Jiang Z, Zhou D, Hormozdiari F, et al; GTEx GWAS Working Group. Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. *Genome Biol.* 2021;22:49. doi: 10.1186/s13059-020-02252-4
93. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, Eyler AE, Denny JC, Nicolae DL, Cox NJ, et al; GTEx Consortium. A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet.* 2015;47:1091–1098. doi: 10.1038/ng.3367
94. Urbut SM, Wang G, Carbonetto P, Stephens M. Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. *Nat Genet.* 2019;51:187–195. doi: 10.1038/s41588-018-0268-8
95. Mancuso N, Freund MK, Johnson R, Shi H, Kichaev G, Gusev A, Pasaniuc B. Probabilistic fine-mapping of transcriptome-wide association studies. *Nat Genet.* 2019;51:675–682. doi: 10.1038/s41588-019-0367-1
96. nycgesearch/ lDetect. Accessed April 06. <https://bitbucket.org/nycgesearch/lDetect>.
97. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* 2014;10:e1004383. doi: 10.1371/journal.pgen.1004383
98. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PD, Burgess S, Howson JM. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nat Commun.* 2021;12:1–18.
99. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, et al; CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet.* 2013;45:25–33. doi: 10.1038/ng.2480
100. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol.* 2016;40:304–314. doi: 10.1002/gepi.21965
101. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol.* 2017;46:1985–1998. doi: 10.1093/ije/dyx102
102. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015;44:512–525. doi: 10.1093/ije/dyv080
103. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. *Clin Chem.* 1995;41:264–270.
104. Souto JC, Almasy L, Borrell M, Garí M, Martínez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. *Circulation.* 2000;101:1546–1551. doi: 10.1161/01.cir.101.13.1546
105. Blondon M, van Hylckama Vlieg A, Wiggins KL, Harrington LB, McKnight B, Rice KM, Rosendaal FR, Heckbert SR, Psaty BM, Smith NL. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. *J Thromb Haemost.* 2014;12:879–886. doi: 10.1111/jth.12560
106. Stone N, Pangilinan F, Molloy AM, Shane B, Scott JM, Ueland PM, Mills JL, Kirke PN, Sethupathy P, Brody LC. Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genes. *PLoS One.* 2011;6:e21851. doi: 10.1371/journal.pone.0021851
107. Trégouët DA, Morange PE. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. *Br J Haematol.* 2018;180:335–345. doi: 10.1111/bjh.15004
108. Folsom AR, Tang W, Weng LC, Roetker NS, Cushman M, Basu S, Pankow JS. Replication of a genetic risk score for venous thromboembolism in whites but not in African Americans. *J Thromb Haemost.* 2016;14:83–88. doi: 10.1111/jth.13193
109. Wolford BN, Zhao Y, Surakka I, Wu K-HH, Yu X, Richter C, Bhatta L, Brumpton BM, Desch K, Thibord F. Multi-ancestry GWAS for venous thromboembolism identifies novel loci followed by experimental validation in zebrafish. Preprint published online June 27, 2022. *MedRxiv.* 2022:2022.2006.2021.22276721.
110. Thibord F, Klarin D, Brody JA, Chen M-H, Levin MG, Chasman DI, Goode EL, Hveem K, Teder-Laving M, Martinez-Perez A. Cross-ancestry investigation of venous thromboembolism genomic predictors. *Circulation.* 2022;146:1225–1242. doi: 10.1161/CIRCULATIONAHA.1122.059675
111. Howard AD, Wang X, Prasad M, Sahu AD, Aniba R, Miller M, Hannehalli S, Chang Y-PC. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. *PLoS One.* 2019;14:e0215911. doi: 10.1371/journal.pone.0215911
112. Rizk NM, El-Menyar A, Egue H, Souleiman Wais I, Mohamed Baluli H, Alali K, Farag F, Younes N, Al Suwaidi J. The Association between Serum LDL Cholesterol and Genetic Variation in Chromosomal Locus 1p13.3 among Coronary Artery Disease Patients. *Biomed Res Int.* 2015;2015:678924. doi: 10.1155/2015/678924
113. Arvind P, Nair J, Jambunathan S, Kakkar VV, Shanker J. CELSR2–PSRC1–SORT1 gene expression and association with coronary artery disease and plasma lipid levels in an Asian Indian cohort. *J Cardiol.* 2014;64:339–346. doi: 10.1016/j.jcc.2014.02.012
114. Pan LA, Chen YC, Huang H, Zhang L, Liu R, Li X, Qiang O, Zeng Z. G771C polymorphism in the MLXIPL gene is associated with a risk of coronary artery disease in the Chinese: a case-control study. *Cardiology.* 2009;114:174–178. doi: 10.1159/000226610
115. Qin J, Tian J, Liu G, Zhang Y, Tian L, Zhen Y, Zhang H, Xu J, Sun X, Fang H. Association between 1p13 polymorphisms and peripheral arterial disease in a Chinese population with diabetes. *J Diabetes Investig.* 2018;9:1189–1195. doi: 10.1111/jdi.12804